BofA analyst Jason Zemansky raised the firm’s price target on Cytokinetics to $85 from $41 and keeps a Neutral rating on the shares. While the firm credits Cytokinetics for the “solid topline results for SEQUOIA,” acknowledging “what looks, at the very least, to be solid competitive positioning,” it argues that further potential upside to shares remains unclear pending greater clinical, regulatory, and competitor clarity. Following yesterday’s data release, BofA is increasing its view of the odds of success for aficamten for oHCM to 95% from 65%, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYTK:
- Here’s Why Cytokinetics (NASDAQ:CYTK) Stock Surged Yesterday
- Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
- Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
- Cytokinetics seeing ‘strong interest’ from strategic suitors, Dealreporter says
- Oppenheimer, Wedbush say buy these biotech stocks for 2024